Endo International Plc agreed to buy Par Pharmaceutical Holdings Inc. from investment firm TPG Capital in a deal valued at $8.05 billion, two months after dropping an effort to purchase Salix Pharmaceuticals Ltd.

The U.S.-Irish drugmaker plans to acquire Par with 18 million Endo shares, valued at $1.55 billion, and $6.5 billion in cash, and will assume Par’s debt, the companies said in a statement Monday. The takeover will create a generic drugs business that is among the top 5 in U.S. sales, the companies said, and will boost Endo’s earnings in the first year.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.